AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03904615 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Collagen Protein
Description: 30 g of collagen protein in flavored water, twice daily, during hospitalization and for 30 days post-discharge
Study NCT03904615 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30 g of maltodextrin in flavored water, twice daily, during hospitalization and for 30 days post-discharge
Study NCT01450800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to placebo will be instructed to take placebo one tablet by mouth daily starting on postoperative day 1 for up to 7 days during catheterization
Study NCT04598958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMPROVE
Description: Health system interventions that include: (1) Multidisciplinary integrated management teams to coordinate patient-focused and outcome-oriented PMTCT and MCH services; (2) Enhanced Positive Health, Dignity, and Prevention (PHDP)-focused counseling and skills-building training and job aids; and (3) Increased early community-based counseling and support for first (antenatal care clinic) ANC attendees
Study NCT00127166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast sodium
Description: Montelukast 5 mg chewable tablet once daily
Study NCT00127166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol xinafoate
Description: Salmeterol 50 mcg dry powder per actuation inhaled twice daily
Study NCT00127166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Description: Fluticasone (50 mcg per actuation) 100 mcg inhaled twice daily
Study NCT00127166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast matching placebo
Description: Matching placebo to montelukast oral tablet administered once daily.
Study NCT00127166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol matching placebo
Description: Matching placebo to salmeterol dry powder for inhalation administered twice daily
Study NCT03926416 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CodaVax-H1N1
Description: Live-attenuated vaccine against influenza A H1N1, A/California/07/2009
Study NCT03926416 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: CodaVax-H1N1
Description: Live-attenuated vaccine against influenza A H1N1, A/California/07/2009
Study NCT03926416 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone quadrivalent
Description: Fluzone® (QuadriFlu - TIV), inactivated, quadrivalent influenza vaccine
Study NCT03926416 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Fluzone quadrivalent
Description: Fluzone® (QuadriFlu - TIV), inactivated, quadrivalent influenza vaccine
Study NCT01348958 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iDXA knee software
Description: Following surgery, subjects who have undergone knee arthroplasty will have the knee that has undergone arthroplasty (post-operative) scanned at least 8 weeks after surgery.~During one visit, each subject will have the post-operative knee scanned 1 time using Lunar orthopedic application, and 3 times with the subject repositioned between scans using the Lunar orthopedic knee application (total of 4 scans). Lunar iDXA measurement procedures will be done
Study NCT01591824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resonant oscillation
Description: Resonant sustained oscillations are applied in the following areas~* general column.~* lumbar muscles, and paraspinal muscles,~* sacral decompression oscillatory~* Opening by lateral vertebral lumbar rhythmic swing.~* Balancing and pelvic decompression~* Swing-lumbar vertebral rotation.
Study NCT01591824 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: column exercise group
Description: * paraspinal muscle stretching exercises~* postural correction~* mobilization exercises thoracic and lumbar~* Motor control exercises
Study NCT01460030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet HCl
Description: Oral administration
Study NCT04305470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleolan (Aminolevulinic Acid Hydrochloride/ALA/ALA-HCI)
Description: One time oral dose on day of surgery (20 mg/kg bodyweight)
Study NCT03116022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Distal estriol
Description: Women using drug 1 mg / 1g at the distal third of the vagina every other night for 12 weeks
Study NCT03116022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaginal Gel
Description: Women using a base water gel lubricant during intercourse
Study NCT01787747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786 Dose 1
Study NCT04429113 — intervention group
Intervention type: DEVICE
Intervention: Maxillary expansion with conventional Quad Helix bonded on molars.
Description: Maxillary expansion with conventional Quad Helix bonded on molars
Study NCT00310492 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: subcutaneous immunotherapy
Description: Updosing by 16 injections to 100,000 SQ-U
Study NCT00310492 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: subcutaneous immunotherapy
Description: Updosing by 16 injections to 100,000 SQ-U
Study NCT02399891 — intervention group
Intervention type: OTHER
Intervention: Quality Assurance Implementation
Study NCT02399891 — intervention group
Intervention type: OTHER
Intervention: Standard of Care
Study NCT03727945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: abdominopelvic exercise and posture
Description: n=21 women received supervised abdominopelvic exercise with previous postural correction. During 12 sessions a specialized physiotherapist supervised to realization of progressive abdominopelvic exercises, previous explain postural correction pelvis, cervical and dorsal zone.
Study NCT03727945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: abdominopelvic exercise
Description: n=21 women received supervised abdominopelvic exercise. During 12 sessions a specialized physiotherapist supervised to realization of progressive abdominopelvic exercises.
Study NCT05484791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Lumbar Rotational Spinal Mobilization Technique
Description: Patients included in the study underwent the lumbar rotational spinal mobilization(LRSM) technique during two sessions per week. The LRSM technique is applied while patients are lying on their side. The uppermost hip and knee are placed in 90 degree flexion, this is to assist rotational stress, and the lower leg is placed in extension. The lower shoulder is strongly pulled; thus, the upper shoulder is positioned toward the posterior and the pelvis moves anteriorly. The clinician stands in front of the patient. They stabilize the upper shoulder with one hand, and place the palm of the other hand behind the hard part of the ilium wing, with forearm horizontal and fingers turned toward the clinician. A rotational force is applied with pressure in the horizontal direction by pulling the hand on the ilium toward the clinician. In this position, 30 slow repeated movements are performed. The same practice is performed on both sides
Study NCT03945916 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dark chocolate
Description: 180 g/d dark chocolate for 15 days followed by exercise testing
Study NCT03945916 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 180 g/d imitation dark chocolate for 15 days followed by exercise testing
Study NCT02263768 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Oral clinical conditions
Description: Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment
Study NCT01787747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786 Dose 2
Study NCT01787747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786 Dose 1/Q Dose 1
Study NCT01787747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786 Dose 1/Q Dose 2
Study NCT01787747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786 Dose 2/Q Dose 2
Study NCT01787747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-923
Study NCT06696196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smart watches(wearable devices)
Description: Participants will be asked to wear two smart watches simultaneously. The first smart watch is a dedicated prototype for validating algorithm developed by MediaTek. The second smart watch is Basis Peak. These watches are going to acquire PPG, body movements, skin temperature, and skin conductance.
Study NCT02707016 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sevoflurane 8%
Description: Sevoflurane 8% (high dose) during anesthesia induction
Study NCT02707016 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sevoflurane 5%
Description: Sevoflurane 5% (low dose) during anesthesia induction
Study NCT06400225 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06400225 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06400225 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT02754544 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct Electrocortical Stimulation
Description: Undergo direct electrocortical stimulation
Study NCT06400225 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT06400225 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06400225 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radionuclide Imaging
Description: Undergo nuclear study
Study NCT06400225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulixertinib
Description: Given PO
Study NCT02515487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain Fitness Program (BFP)
Description: The program is designed to improve processing speed of auditory information and attention. The BFP is comprised of six computerized subtests that continuously adjust in the level of difficulty to maintain an 85% correct response rate. The subtest exercises include discrimination of confusable syllables, recognition of sequences of syllables, matching pairs of confusable syllables, reconstruction of sequences of verbal instructions and identification of details in a verbally presented story. Participants will participate in 40 one-hour training sessions over a 12 week period to complete all cognitive remediation training sessions. Since this intervention is presented both visually and verbally, noise cancelling headphones will be provided to the participants.
Study NCT01057173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Implantation
Description: Retrograde trans-femoral or trans-subclavian aortic valve implantation with the Medtronic CoreValve System(TM) bio-prosthesis (third generation system, 18 Fr, CE mark approved)
Study NCT01057173 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Aortic Valve Replacement
Description: Conventional surgical aortic valve replacement with a bio-prosthesis using normothermic cardiopulmonary bypass and cold blood cardioplegia cardiac arrest
Study NCT03581162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Carotid Ultrasound and venous blood sampling
Description: Carotid ultrasound and blood sampling
Study NCT02079233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cross-Linked Polyelectrolyte (CLP)
Description: CLP was administered orally, in capsules, for 7 consecutive days.
Study NCT02754544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrocorticography
Description: Undergo electrocorticography
Study NCT02684331 — intervention group
Intervention type: OTHER
Intervention: Cardiac Magnetic Resonance Imaging (CMR)
Description: An extensive explorative CMR protocol, including time/volume curves of LV and LA, rest and stress perfusion (with Adenosin) and time/volume curve of LA after chronotropic stress with Glycopyrrolate, further flow measurements and T1 mapping.
Study NCT02684331 — intervention group
Intervention type: OTHER
Intervention: Echocardiography
Description: Standard measurements and strain.
Study NCT02684331 — intervention group
Intervention type: OTHER
Intervention: Bood samples
Description: HbA1c, Glucose, Hgb, Creatinin, Sodium, Potassium, Total cholesterol, LDL cholesterol, HDL cholesterol, Free fatty acids, ALAT, Urinary albumin, NT-proBNP, ANP, suPAR, Copeptin, Proendothelin, proCNP, Soluble ST2, Galectin-3
Study NCT03944109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1209
Description: Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous
Study NCT03944109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous
Study NCT01931345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing Counseling
Description: Counseling developed by the research team based on a motivational interviewing approach
Study NCT01931345 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard counseling
Description: Counseling based on Quebec guidelines for rapid HIV testing
Study NCT02428348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview about prototype EEG-cap
Study NCT03522025 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unicompartmental Knee Arthroplasty (UKA)
Description: Unicompartmental Knee Arthroplasty (UKA) is a less invasive treatment option compared to Total Knee Arthroplasty (TKA) for patients with primary anteromedial knee osteoarthritis.
Study NCT01872507 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback training
Description: usual treatment +12 biofeedback training
Study NCT03920280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LID015385 contact lenses
Description: Investigational silicone hydrogel contact lenses
Study NCT03920280 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfilcon A soft contact lenses
Description: Commercially available silicone hydrogel contact lenses
Study NCT03920280 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CLEAR CARE
Description: Hydrogen peroxide-based cleaning and disinfecting system
Study NCT03920280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLEAR CARE
Description: Hydrogen peroxide-based cleaning and disinfecting system
Study NCT02103101 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Measurement of Plasma Concentrations of NOACs
Description: Plasma concentrations of dabigatran, rivaroxaban or apixaban will be measured using High Performance Liquid Chromatography (HPLC) coupled with tandem mass spectrometry (MS/MS). Blood samples will be taken in an EDTA tube and rapidly centrifugated. Plasma will be aliquoted and frozen at minus 80 degrees Celsius for later analysis.
Study NCT02103101 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Identification of ABCB1 polymorphisms coding for P-gp
Description: To investigate the existence of a relation between polymorphisms of ABCB1 and plasma concentrations of new oral anticoagulants, the SNaPshot® Multiplex System will be used enabling multiplexing of SNPs (single nucleotide polymorphisms) of the ABCB1 gene (namely rs4148738, rs2235046, rs1128503, rs10276036, rs1202169, rs1202168, rs1202167).
Study NCT03252990 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PET-MRI
Description: Additional 18F-choline PET-MRI examination
Study NCT03252990 — intervention group
Intervention type: PROCEDURE
Intervention: Optical Coherence Tomography
Description: Additional optical coherence tomography (OCT) examination (during the already planned routine PCI procedure)
Study NCT02359864 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 5 daily fractions of 2 Gy
Description: Whole Brain Irradiation to treat Alzheimer's Disease
Study NCT02359864 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 10 daily fractions of 2 Gy
Description: Whole Brain Irradiation to treat Alzheimer's Disease
Study NCT00487695 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: confocal laser endomicroscopy (CLE)
Description: Confocal laser endomicroscopy is done by performing standard endoscopy, then using a microscope on the tip of the endoscope to obtain microscopic images of the mucosa. This is done by gently placing the tip of the endoscope on the lining of the esophagus.
Study NCT00487695 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard endoscopy (EGD)
Description: Standard upper endoscopy (EGD) is performed using a regular upper endoscope, which is used to look at the lining of the esophagus.
Study NCT01876745 — intervention group
Intervention type: DRUG
Intervention: eptacog alfa (activated)
Description: Patients will be treated according to routine clinical practice at the direction of the treating physician. Data will be collected once a year after patient is registered with baseline visit until end of the study.
Study NCT01120691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
Study NCT01120691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVA237
Description: NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
Study NCT01120691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Description: Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
Study NCT01120691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol/albuterol
Description: As needed throughout the study
Study NCT01120691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol/albuterol
Description: As needed throughout the study
Study NCT02571933 — intervention group
Intervention type: OTHER
Intervention: Pre-treatment Faces Pain Scale - Revised
Description: Patients will be asked to answer the Faces Pain Scale - Revised as an assessment of pain prior to standard analgesia dosing.
Study NCT02571933 — intervention group
Intervention type: OTHER
Intervention: Post-treatment Faces Pain Scale - Revised
Description: Patients will be asked to answer the Faces Pain Scale - Revised 1-2 hours after receiving standard analgesia as an assessment of pain.
Study NCT02571933 — intervention group
Intervention type: OTHER
Intervention: Cognitive interview
Description: Patients will answer a series of questions pertaining to the pain scale's ease of use, intuitive nature, and cultural appropriateness.
Study NCT02889393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: Daily 0.05 mg/kg Teduglutide administered subcutaneously.
Study NCT02889393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: The standard of care treatment of ECF which includes meticulous wound care, optimizations of nutrition, use of acid-suppression medications and anti-motility agents as per treating physician discretion.
Study NCT00697918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RWJ-333369
Description: 100 mg to 400 mg twice daily
Study NCT03220256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: The dose of lamotrigine (0.1mg) started to increase and gradually increased according to the drug tolerance induction protocol, and the efficacy was evaluated by dosing to the commercial capacity (100mg bid) within 2 weeks. In addition, the ratio of regulatory T cells was measured before lamotrigine administration, and the proportion of regulatory T cells was measured by two-week administration of lamotrigine after tolerance induction protocol. Add 6 ml of EDTA tube to each cryovial, and dispense 1 ml each in cryovial. After the appropriate number of patients of the same phenotype were collected, the analysis was performed.
Study NCT04147169 — intervention group
Intervention type: BEHAVIORAL
Intervention: Focused end-of-life conversations to promote connections among patients, family members and clinicians.
Description: All eligible patients and families who were invited to participate in wish elicitation and implementation. For family interviews, criterion sampling was used. For the clinician focus groups, criterion sampling was used, based on involvement in the care of a 3WP patient. For the manager/hospital administrator interviews, purposive sampling was used, based on relevant leadership positions. Investigators employed qualitative and quantitative methods to collect and analyze data. Quantitative data include characteristics of patients, families and clinicians, questionnaire responses from families who agree to interviews, and clinicians who agree to focus groups, respectively, types of wishes elicited and implemented, and their cost. Qualitative data was obtained through individual family interviews, inter-professional clinician focus groups, project team field notes, additional ideas about the costs and benefits of the project from manager interviews, and analysis of project documents.